TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ImExHS Limited ( (AU:IME) ) has issued an announcement.
IMEXHS Limited reported its financial results for the first half of FY25, showing a 4% increase in revenue to $13.7 million and an 11% rise in annualized recurring revenue to $32.8 million. The company successfully launched its next-generation radiology platform, Aquila+, which has been well-received in the market, securing significant new contracts and expanding its partner program. Despite challenges such as currency fluctuations, IMEXHS maintained a positive underlying EBITDA and strengthened its balance sheet through capital raising. The company aims to accelerate sales and maintain margin discipline in the second half of the year.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
More about ImExHS Limited
IMEXHS Limited is an innovative provider of cloud-based medical imaging software and radiology services, operating across 18 countries. The company focuses on delivering advanced radiology platforms and services, with a strong emphasis on recurring revenue and international market expansion.
Average Trading Volume: 32,732
Technical Sentiment Signal: Sell
Current Market Cap: A$12.07M
See more data about IME stock on TipRanks’ Stock Analysis page.